CreationDate: 10/15/2008 1:09:58 PM
Sample Name: Sample 5
Sample Description: 2007-2.5
Method: XSR_MDA.M last changed 10/15/2008 1:09:47 PM

Signal: DAD1 A, Sig=270,8 Ref=500,100
     Time Type      Area    Height     Width     Start       End
----------------------------------------------------------------
    0.897 BB       0.372     0.273     0.021     0.873     0.930 
    1.450 BB       0.339     0.287     0.018     1.429     1.480 
    1.588 BB     726.354   265.055     0.040     1.561     1.762 
    2.538 MM       0.420     0.363     0.019     2.513     2.564 
    2.662 BB       0.361     0.289     0.020     2.638     2.697 

Signal: DAD1 B, Sig=254,10 Ref=450,100
     Time Type      Area    Height     Width     Start       End
----------------------------------------------------------------
    1.589 BB     208.879    76.089     0.041     1.557     1.711 
    2.538 BB       1.313     1.063     0.019     2.514     2.571 
    2.662 BB       0.270     0.227     0.019     2.637     2.692 


   RetTime       Type CalibPeakType                       Signalname          Amount Compound
---------------------------------------------------------------------------------------------------------
     0.897   Expected          Main    DAD1 A, Sig=270,8 Ref=500,100     0.542 µg/ml o-desm tramadol (D)
     1.450   Expected          Main    DAD1 A, Sig=270,8 Ref=500,100     0.518 µg/ml trans- tramadol (A)
     1.589   Expected          Main   DAD1 B, Sig=254,10 Ref=450,100  1010.687 µg/ml TRAMADOL
     1.588   Expected     NewIgnore    DAD1 A, Sig=270,8 Ref=500,100  1010.687 µg/ml TRAMADOL
     2.538   Expected          Main    DAD1 A, Sig=270,8 Ref=500,100     0.505 µg/ml des-hyd cis tramadol (C)
     2.538   Expected     NewIgnore   DAD1 B, Sig=254,10 Ref=450,100     0.505 µg/ml des-hyd cis tramadol (C)
     2.662   Expected          Main    DAD1 A, Sig=270,8 Ref=500,100     0.529 µg/ml des-hyd trans tramadol (B)
     2.662   Expected     NewIgnore   DAD1 B, Sig=254,10 Ref=450,100     0.529 µg/ml des-hyd trans tramadol (B)

-------------------------------------------------------------------------------------------------------------

